A tiny electronic eye implant is giving people with incurable vision loss the ability to see again, according to a groundbreaking clinical trial published this week in the New England Journal of Medicine. The results mark a major step forward in restoring sight to those affected by age-related macular degeneration (AMD), one of the world’s leading causes of blindness.
The implant, designed to restore central vision lost to advanced AMD, is surgically placed under the retina and connects to a special pair of glasses. It was tested on 38 elderly patients across five European countries who were living with geographic atrophy — a late-stage form of dry AMD that currently has no effective treatment.
Before the procedure, all participants had only limited peripheral vision. But within a year of receiving the implant, 84% of the patients regained the ability to read letters, numbers, and words using the artificial vision system. Nearly 70% reported being satisfied with the device’s performance.
“This study confirms that, for the first time, we can restore functional central vision in patients blinded by geographic atrophy,” said Dr. Frank Holz, lead researcher and chair of ophthalmology at the University Hospital of Bonn in Germany. “The implant represents a paradigm shift in treating late-stage AMD.”
The system works by combining the implant with a high-tech pair of glasses that contain a miniature video camera. The glasses capture visual scenes, process them, and project the images onto the implant using near-infrared light. The implant then converts the light into electrical signals that stimulate retinal cells, recreating the flow of visual information to the brain.
Many trial participants were able to read again and recognize faces for the first time in years, marking a life-changing improvement in their independence and quality of life.
The technology was originally developed by the French company Pixium Vision, which went bankrupt last year. Its assets were later acquired by the U.S.-based Science Corporation, a firm specializing in brain-computer interface technologies. Science Corporation has since applied for regulatory approval to sell the implant in the European Union and hopes it could be available to patients as early as next year.
The company said the current version of the device would initially target patients with advanced AMD and severe vision loss, while a more advanced model is already in development.
If approved, the implant could become the first commercially available device capable of restoring central vision to patients previously considered untreatable.
